Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence
- PMID: 29570821
- DOI: 10.1002/pros.23511
Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence
Abstract
Background: Rates of metastatic progression (MP) and prostate cancer mortality (PCSM) are variable after biochemical recurrence (BCR) in patients who underwent radical prostatectomy (RP). To describe long-term oncological outcomes of BCR patients and to analyze risk factors for further outcomes in these men with a special focus on RP-BCR time.
Methods: We retrospectively analyzed the data of 5509 RP patients treated between 1992 and 2006. Of those, we included 1321 patients who experienced BCR (PSA level ≥0.2 ng/mL) and did not receive any neoadjuvant or adjuvant therapy. Kaplan-Meier and time dependent Cox regression models were used.
Results: Median follow-up was 121 months. MP was recorded in 177 (13.4%), PCSM in 126 (9.5%), and overall mortality (OM) in 264 (20.0%) patients. Patients with MP had worse tumor characteristics such as higher Gleason Scores (GS), rapid PSA doubling-time (DT), and shorter RP-BCR time intervals. MP-free, PCSM-free, and overall survival rates were significantly worse in patients with RP-BCR time of <12 months versus patients with 12-35.9 or ≥36 months (P ≤ 0.001). Besides higher GS and rapid PSA-DT, RP-BCR time independently predicted MP, PCSM, and OM in multivariable regression analyses. Relative to the intermediate and longest RP-BCR time interval, the shortest interval (<12) carried the highest risk for all three endpoints.
Conclusions: Only a small proportion of BCR patients proceed to MP or PCSM. Besides higher GS and rapid PSA-DT a shorter RP-BCR interval (<12 months) heralds the most aggressive phenotype for progression to all three examined endpoints: MP, PCSM, and OM.
Keywords: BCR; outcomes; prostate cancer; radical prostatectomy; time to BCR.
© 2018 Wiley Periodicals, Inc.
Similar articles
-
Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.Eur Urol. 2015 Feb;67(2):204-9. doi: 10.1016/j.eururo.2014.09.017. Epub 2014 Oct 5. Eur Urol. 2015. PMID: 25294696
-
Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):960-7. doi: 10.1016/j.ijrobp.2013.09.015. Epub 2013 Oct 23. Int J Radiat Oncol Biol Phys. 2013. PMID: 24351411
-
Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4. BJU Int. 2013. PMID: 22487441
-
Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.Eur Urol. 2019 Jun;75(6):967-987. doi: 10.1016/j.eururo.2018.10.011. Epub 2018 Oct 17. Eur Urol. 2019. PMID: 30342843
-
Markers and meaning of primary treatment failure.Urol Clin North Am. 2003 May;30(2):377-401. doi: 10.1016/s0094-0143(02)00176-3. Urol Clin North Am. 2003. PMID: 12735513 Review.
Cited by
-
Time to biochemical relapse after radical prostatectomy and efficacy of salvage radiotherapy in patients with prostate cancer.Int J Clin Oncol. 2019 Oct;24(10):1238-1246. doi: 10.1007/s10147-019-01463-5. Epub 2019 May 13. Int J Clin Oncol. 2019. PMID: 31087170
-
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.J Nucl Med. 2022 Jan;63(1):76-80. doi: 10.2967/jnumed.121.262821. Epub 2021 Oct 7. J Nucl Med. 2022. PMID: 34620731 Free PMC article.
-
Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis.Cancers (Basel). 2022 Jan 31;14(3):740. doi: 10.3390/cancers14030740. Cancers (Basel). 2022. PMID: 35159007 Free PMC article.
-
The Prognostic Value of Perioperative Factors on Biochemical Recurrence in Patients Undergoing Radical Prostatectomy.Res Rep Urol. 2025 May 27;17:185-194. doi: 10.2147/RRU.S500506. eCollection 2025. Res Rep Urol. 2025. PMID: 40453579 Free PMC article.
-
Detecting recurrent prostate Cancer using multiparametric MRI, influence of PSA and Gleason grade.Cancer Imaging. 2021 Jan 6;21(1):3. doi: 10.1186/s40644-020-00373-4. Cancer Imaging. 2021. PMID: 33407861 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous